Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

26.1%

6 terminated/withdrawn out of 23 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

17%

4 trials in Phase 3/4

Results Transparency

27%

4 of 15 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

N/A
11(57.9%)
Phase 4
3(15.8%)
Phase 1
2(10.5%)
Phase 2
2(10.5%)
Phase 3
1(5.3%)
19Total
N/A(11)
Phase 4(3)
Phase 1(2)
Phase 2(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT04428008Phase 2Completed

Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients

Role: collaborator

NCT02373215Phase 1Completed

Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

Role: collaborator

NCT04095039Not ApplicableTerminated

HiLo: Pragmatic Trial of Higher vs Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis

Role: collaborator

NCT02651428Phase 3Completed

Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

Role: collaborator

NCT05032417Not ApplicableUnknown

Evaluating the Implementation of Evidence-Based Kidney Nutrition Practice Guidelines: The AUGmeNt Study Protocol

Role: collaborator

NCT04495907Completed

COVID-19 Progression in End-Stage Kidney Disease

Role: lead

NCT04495764Completed

Registry of Sustained Immunity to COVID-19 Among ESKD Patients

Role: lead

NCT03791814Phase 4Withdrawn

A Prospective Cohort Study to Improve HCV Care in Dialysis Patients

Role: collaborator

NCT02019225Not ApplicableTerminated

A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration

Role: collaborator

NCT02593149Not ApplicableCompleted

Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap

Role: collaborator

NCT02730676Completed

Comparison of Pharmacokinetic Parameters Between Adopters of Electronic Cigarettes and a Historical Sample of Combustible Cigarette Smokers

Role: collaborator

NCT02323438Not ApplicableCompleted

Assess Biomarkers of Tobacco Exposure and Nicotine Pharmacokinetics in Smokers After a 5-Day In-Clinic Confinement Switch to an Electronic Cigarette or Nicotine Gum

Role: collaborator

NCT03105804Not ApplicableCompleted

CSD170301: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake in Smokers From Four Different Electronic Cigarettes

Role: collaborator

NCT03234010Not ApplicableCompleted

CSD170303: Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes

Role: collaborator

NCT03233997Not ApplicableCompleted

CSD170302: Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes

Role: collaborator

NCT03063047Not ApplicableCompleted

CSD1603: A Crossover Study to Evaluate the Exposure to "Tar" and Nicotine From 100s Menthol Cigarette Products

Role: collaborator

NCT03063034Not ApplicableCompleted

CSD1602: A Crossover Study to Evaluate the Exposure to "Tar" and Nicotine From Two King Size Menthol Cigarette Products

Role: collaborator

NCT02500667Phase 1Completed

A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects

Role: collaborator

NCT02044614Not ApplicableTerminated

Adjuvant Peritoneal Dialysis on a Background of Thrice-Weekly Hemodialysis

Role: lead

NCT01623583Phase 4Terminated

Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias

Role: lead